- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03525366
Prospective Evaluation Of Outcomes For Patients Undergoing Radiofrequency Ablation (RFA) Using HALO Ultra Device For Gastric Antral Vascular Ectasia (GAVE) (GAVE)
The purpose: To determine the safety and efficacy of Radiofrequency Ablation (RFA) HALO Ultra system in patients with Gastric Antral Vascular Ectasia patient cohort (GAVE).
Research design: This is a prospective observational study. Procedure Used: Radiofrequency Ablation
Risks and potential benefits:
There are no risks associated with this study as it is a retrospective chart review. Potential benefits include the knowledge gained from this study which may be of help to patients in the future.
Importance of knowledge that may reasonably be expected to result The knowledge gained from this study may be of help to other patients in the future.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to see how well study device works at treating people with Gastric Antral Vascular Ectasia (GAVE). The device has already been approved by the Food and Drug Administration (FDA) and is a part of standard of care. You have been invited to join this research study because you require diagnostic or therapeutic evaluation of the Gastric Antral Vascular Ectasia by RFA.
This is a single -site study being performed at the University of Texas Health Science Center. The study will enroll a total 1000 patients with GAVE. This study is purely observational and will collect clinical information regarding your GAVE
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Prithvi B Patil, MS
- Phone Number: 713-500-6654
- Email: prithvi.b.patil@uth.tmc.edu
Study Contact Backup
- Name: Nirav Thosani, MD
- Phone Number: 7135006457
- Email: nirav.thosani@uth.tmc.edu
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- Memorial Hermann Hospital
-
Contact:
- Prithvi Patil, MS
- Phone Number: 713-500-6654
- Email: prithvi.b.patil@uth.tmc.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- In-patients
- Patients diagnosed with GAVE
- Patients undergoing radiofrequency ablation with HALO ULTRA device
Exclusion Criteria:
- Patients who were not diagnosed with GAVE
- Patients undergoing RFA with HALO ULTRA device for diseases other than GAVE.
- Patients with GAVE receiving other endoscopic therapies like argon plasma coagulation (APC) or radiofrequency ablation (RFA) with devices other than HALO ULTRA
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Cross-Sectional
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of RFA therapy sessions with the HALO ULTRA device
Time Frame: Up to 1 year after first RFA session with the HALO ULTRA device
|
Patients will be followed up until the time that they achieve resolution of Gastric Antral Vascular Ectasia (GAVE) lesions, which may be up to 1 year.
|
Up to 1 year after first RFA session with the HALO ULTRA device
|
Hemoglobin level
Time Frame: Before the first RFA session with HALO ULTRA device.
|
Before the first RFA session with HALO ULTRA device.
|
|
Hemoglobin level
Time Frame: At the time of resolution of GAVE lesions, which is up to 1 year after first RFA session with HALO ULTRA device.
|
Hemoglobin level will be assessed at the time the patient achieves resolution of Gastric Antral Vascular Ectasia (GAVE) lesions, which may be up to 1 year.
|
At the time of resolution of GAVE lesions, which is up to 1 year after first RFA session with HALO ULTRA device.
|
Number of patients who require blood transfusion
Time Frame: Before the first RFA session with HALO ULTRA device
|
Before the first RFA session with HALO ULTRA device
|
|
Number of patients who require blood transfusion
Time Frame: At the time of resolution of GAVE lesions, which is up to 1 year after first RFA session with HALO ULTRA device.
|
Patients will be followed up until the time that they achieve resolution of Gastric Antral Vascular Ectasia (GAVE) lesions, which may be up to 1 year.
|
At the time of resolution of GAVE lesions, which is up to 1 year after first RFA session with HALO ULTRA device.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Nirav Thosani, MD MHA, The University of Texas Health Science Center, Houston
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSC-MS-15-0449
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Antral Vascular Ectasia
-
Assiut UniversityNot yet recruitingGAVE - Gastric Antral Vascular Ectasia
-
H. Lee Moffitt Cancer Center and Research InstituteColumbia University; University Hospitals Cleveland Medical Center; Geisinger... and other collaboratorsSuspendedBleeding | GAVE - Gastric Antral Vascular Ectasia | Bleeding GastricUnited States
-
University of AlbertaCompletedGastric Antral Vascular EctasiaCanada
-
Mayo ClinicNot yet recruitingCirrhosis | Gastric Antral Vascular EctasiaUnited States
-
Institute of Liver and Biliary Sciences, IndiaNot yet recruitingLiver Cirrhosis | Gastric Antral Vascular EctasiaIndia
-
Alexandria UniversityCompletedGastric Antral Vascular EctasiaEgypt
-
Shanghai Jiao Tong University School of MedicineCompletedGastric Antral Vascular Ectasia | Angiodysplasia | Obscure Gastrointestinal Bleeding | Thalidomide
-
Interventional Cardiovascular Innovation Group,...Not yet recruitingCoronary Artery Ectasia
-
Assiut UniversityRecruiting
Clinical Trials on Radiofrequency ablation
-
Assistance Publique - Hôpitaux de ParisTerminatedHepatocellular CancerFrance
-
Xijing HospitalUnknown
-
Oxford University Hospitals NHS TrustRoyal Bournemouth and Christchurch Hospitals NHS Foundation TrustCompleted
-
Allevio Pain Management ClinicRecruitingShoulder Pain Chronic | Faceto-genic Neck Pain | Faceto-genic HeadacheCanada
-
Southwest Hospital, ChinaCompleted
-
Mansoura UniversityUnknownChronic Knee OsteoarthritisEgypt
-
University of CalgaryRecruitingOsteoarthritis, KneeCanada
-
Assistance Publique - Hôpitaux de ParisCompletedHepatocellular CarcinomasFrance
-
Aalborg University HospitalOdense University Hospital; St. Antonius HospitalTerminatedParoxysmal Atrial Fibrillation.Netherlands, Denmark
-
Ziekenhuis Oost-LimburgBelgium Health Care Knowledge Centre; Klinische Epidemiologie en Medical Technology...RecruitingKnee Osteoarthritis | Chronic Knee Pain | Persistent Postsurgical PainBelgium, Netherlands